| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
DBCO-PEG24-Maleimide is a chemical linker and does not have a specific pharmacological target. It is designed to facilitate the conjugation of biomolecules through two orthogonal chemistries: the DBCO group reacts with azides via SPAAC click chemistry, and the maleimide group reacts with thiols (e.g., cysteine residues in proteins) via Michael addition. These reactions enable the creation of bioconjugates for drug delivery, imaging, and diagnostic applications without the need for toxic copper catalysts.
|
|---|---|
| ln Vitro |
As a chemical linker, DBCO-PEG24-Maleimide itself does not possess biological activity. Its utility lies in its ability to conjugate biomolecules efficiently and specifically. The PEG24 spacer provides increased solubility, reduced aggregation, and decreased immunogenicity for the resulting conjugates. The compound is not evaluated for traditional in vitro activity such as IC50 values against cell lines.
|
| ln Vivo |
DBCO-PEG24-Maleimide is not a therapeutic compound and is not evaluated for in vivo activity in the traditional sense. However, conjugates formed using this linker can be used for in vivo applications such as targeted drug delivery, imaging, and antibody-drug conjugates. The PEG24 spacer significantly influences the pharmacokinetic properties of the resulting conjugates by increasing hydrodynamic volume, reducing renal clearance, and decreasing immunogenicity.
|
| Enzyme Assay |
Non-cell-based protocols for DBCO-PEG24-Maleimide involve conjugation chemistry and characterization of the resulting conjugates. A typical conjugation procedure includes: dissolving DBCO-PEG24-Maleimide in anhydrous DMSO or appropriate buffer, adding to a solution of the thiol-containing biomolecule (e.g., protein with free cysteine) in PBS buffer (pH 6.5–7.5), incubating at room temperature for 1–4 hours. For azide conjugation, the DBCO group reacts with azide-containing molecules in PBS buffer at room temperature for 1–24 hours. Conjugation efficiency is confirmed by SDS-PAGE, mass spectrometry, or HPLC.
|
| Cell Assay |
Cellular assays with DBCO-PEG24-Maleimide conjugates typically involve labeling cell surface proteins or internalized molecules. A representative protocol includes: treating cells with a thiol-reactive probe or azide-modified biomolecule, washing, incubating with DBCO-PEG24-Maleimide conjugates at 1–10 μM for 30–60 minutes at 37°C, washing to remove unbound material, and analyzing by flow cytometry or fluorescence microscopy. The maleimide-thiol reaction is selective at pH 6.5–7.0.
|
| Animal Protocol |
In vivo animal studies with DBCO-PEG24-Maleimide conjugates are conducted depending on the specific application, such as imaging or drug delivery. A typical protocol involves intravenous administration of the conjugate into mouse models, followed by monitoring of distribution, target engagement, and therapeutic efficacy using appropriate detection methods. The PEG24 spacer helps to prolong circulation time and reduce immunogenicity compared to shorter PEG linkers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are determined for the DBCO-PEG24-Maleimide conjugate rather than the linker itself. The PEG24 spacer significantly influences the PK properties of the resulting conjugates by increasing hydrodynamic volume to approximately 55–60 kDa, reducing renal clearance, and decreasing immunogenicity. DBCO-PEG24-Maleimide is stored as an oil at -20°C under nitrogen to prevent oxidation of the maleimide group.
|
| Toxicity/Toxicokinetics |
As a research linker, DBCO-PEG24-Maleimide is not intended for human therapeutic use, and comprehensive toxicological data are not available. Standard laboratory safety precautions should be followed when handling the compound. The maleimide group is reactive with thiols and should be handled with appropriate care to avoid unintended reactions. The compound is typically stored at -20°C, protected from light and moisture.
|
| References | |
| Additional Infomation |
DBCO-PEG24-Maleimide (CAS 2924872-84-2) is a versatile heterobifunctional linker with a long PEG24 spacer for bioconjugation applications. The DBCO group enables copper-free click chemistry with azides, eliminating the need for toxic copper catalysts. The maleimide group provides thiol-specific conjugation, enabling site-specific labeling of proteins and peptides. The PEG24 spacer provides excellent aqueous solubility and reduces the immunogenicity of conjugates, making this linker particularly suitable for preparing antibody-drug conjugates, protein therapeutics, and targeted imaging probes for in vivo applications.
|
| Exact Mass |
1554.819
|
|---|---|
| CAS # |
2924872-84-2
|
| PubChem CID |
155906774
|
| Appearance |
ointment
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
29
|
| Rotatable Bond Count |
81
|
| Heavy Atom Count |
109
|
| Complexity |
2250
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C2=CC=CC=C2C#CC3=CC=CC=C3N1C(=O)CCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN4C(=O)C=CC4=O
|
| InChi Key |
ABMCAJWJYKSVIS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C76H122N4O29/c81-72(14-18-79-74(83)11-12-75(79)84)78-17-20-87-22-24-89-26-28-91-30-32-93-34-36-95-38-40-97-42-44-99-46-48-101-50-52-103-54-56-105-58-60-107-62-64-109-66-65-108-63-61-106-59-57-104-55-53-102-51-49-100-47-45-98-43-41-96-39-37-94-35-33-92-31-29-90-27-25-88-23-21-86-19-15-73(82)77-16-13-76(85)80-67-70-7-2-1-5-68(70)9-10-69-6-3-4-8-71(69)80/h1-8,11-12H,13-67H2,(H,77,82)(H,78,81)
|
| Chemical Name |
N-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[3-(2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-3-oxopropyl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-3-(2,5-dioxopyrrol-1-yl)propanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
